title: Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease.
abstract: An 11-year-old girl with active subfoveal choroidal neovascularization associated with Best disease responded well to a single intravitreal injection of combined bevacizumab and triamcinolone acetonide. Choroidal neovascularization regressed, subretinal serous fluid resorbed, and visual acuity improved from 20/400 to 20/100. The patient remained stable for 6 months after injection.
authors.affiliation: Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Cakir
authors.forename: Osman
authors.initials: O
authors.lastname: Cekiç
authors.forename: O Faruk
authors.initials: OF
authors.lastname: Yilmaz
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D003317:Corneal Dystrophies, Hereditary / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D041623:Tomography, Optical Coherence; D014221:Triamcinolone / Q000008:administration & dosage*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014221:Triamcinolone; D000068258:Bevacizumab